
Krsnaa Diagnostics (KRSNAA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.9B
Gross Profit
1.3B
68.32%
Operating Income
310.3M
16.67%
Net Income
206.8M
11.11%
Balance Sheet Metrics
Total Assets
12.8B
Total Liabilities
4.0B
Shareholders Equity
8.8B
Debt to Equity
0.45
Cash Flow Metrics
Revenue & Profitability Trend
Krsnaa Diagnostics Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 7.2B | 6.2B | 4.9B | 4.6B | 4.0B |
Cost of Goods Sold | 2.3B | 2.1B | 1.6B | 1.7B | 1.9B |
Gross Profit | 4.9B | 4.1B | 3.3B | 2.9B | 2.0B |
Gross Margin % | 67.9% | 66.7% | 68.1% | 63.1% | 51.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 130.1M | 113.4M | 82.5M | 118.2M |
Other Operating Expenses | 1.6B | 1.3B | 1.1B | 842.9M | 611.7M |
Total Operating Expenses | 1.6B | 1.5B | 1.2B | 925.4M | 729.9M |
Operating Income | 1.0B | 697.5M | 692.4M | 903.4M | 568.9M |
Operating Margin % | 14.2% | 11.3% | 14.2% | 19.8% | 14.3% |
Non-Operating Items | |||||
Interest Income | - | 167.6M | 181.2M | 149.1M | 122.2M |
Interest Expense | 246.5M | 140.9M | 64.4M | 168.6M | 249.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.0B | 700.1M | 802.0M | 865.1M | 3.0B |
Income Tax | 250.8M | 131.7M | 180.9M | 181.2M | 1.1B |
Effective Tax Rate % | 24.4% | 18.8% | 22.6% | 20.9% | 37.4% |
Net Income | 776.1M | 568.4M | 621.1M | 683.9M | 1.8B |
Net Margin % | 10.8% | 9.2% | 12.8% | 15.0% | 46.6% |
Key Metrics | |||||
EBITDA | 2.2B | 1.6B | 1.4B | 1.5B | 1.1B |
EPS (Basic) | ₹24.04 | ₹17.90 | ₹19.78 | ₹22.89 | ₹58.90 |
EPS (Diluted) | ₹23.56 | ₹17.31 | ₹19.29 | ₹22.88 | ₹58.90 |
Basic Shares Outstanding | 32282862 | 31746185 | 31397613 | 29876508 | 31397613 |
Diluted Shares Outstanding | 32282862 | 31746185 | 31397613 | 29876508 | 31397613 |
Income Statement Trend
Krsnaa Diagnostics Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 38.4M | 23.8M | 227.2M | 884.5M | 246.8M |
Short-term Investments | 928.8M | 1.7B | 860.8M | 1.5B | 1.3B |
Accounts Receivable | 2.8B | 1.8B | 731.0M | 578.7M | 724.7M |
Inventory | 294.8M | 358.1M | 250.7M | 91.7M | 72.1M |
Other Current Assets | 105.3M | 124.7M | -10.0K | -80.0K | - |
Total Current Assets | 4.1B | 4.2B | 2.2B | 3.3B | 2.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.7B | 236.1M | 191.4M | 133.2M | 95.6M |
Goodwill | 29.5M | 24.3M | 28.3M | 23.2M | 12.3M |
Intangible Assets | - | 24.3M | 28.3M | 23.2M | 12.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 406.2M | 591.4M | 10.0K | 114.6M | - |
Total Non-Current Assets | 8.7B | 7.5B | 6.9B | 5.4B | 3.6B |
Total Assets | 12.8B | 11.7B | 9.1B | 8.8B | 6.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 971.3M | 823.2M | 621.2M | 773.0M | 785.6M |
Short-term Debt | 1.6B | 1.2B | 82.0M | 79.2M | 638.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 54.2M | 92.0M | 22.9M | 147.5M | - |
Total Current Liabilities | 3.1B | 2.8B | 991.9M | 1.2B | 1.8B |
Non-Current Liabilities | |||||
Long-term Debt | 471.6M | 418.8M | 242.8M | 330.7M | 1.7B |
Deferred Tax Liabilities | 225.9M | 164.3M | 127.6M | 78.0M | 107.0M |
Other Non-Current Liabilities | - | - | 70.0K | 158.2M | - |
Total Non-Current Liabilities | 934.4M | 806.4M | 719.6M | 707.2M | 1.9B |
Total Liabilities | 4.0B | 3.6B | 1.7B | 1.9B | 3.7B |
Equity | |||||
Common Stock | 161.4M | 161.4M | 157.0M | 157.0M | 65.0M |
Retained Earnings | - | 1.3B | 815.0M | 271.9M | -412.3M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.8B | 8.1B | 7.4B | 6.8B | 2.3B |
Key Metrics | |||||
Total Debt | 2.0B | 1.6B | 324.8M | 409.9M | 2.3B |
Working Capital | 1.1B | 1.4B | 1.2B | 2.1B | 643.3M |
Balance Sheet Composition
Krsnaa Diagnostics Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.0B | 700.1M | 802.0M | 865.1M | 3.0B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 40.4M | 9.0M | 6.7M | 12.4M | 8.2M |
Working Capital Changes | -1.2B | -1.1B | -205.8M | 40.6M | -260.3M |
Operating Cash Flow | 2.4M | -499.1M | 515.4M | 973.1M | 2.8B |
Investing Activities | |||||
Capital Expenditures | -1.1B | -1.9B | -1.3B | -1.3B | -648.4M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -312.5M | - | 0 | -1.3B | -57.0M |
Investment Sales | 254.4M | 537.4M | 156.9M | - | - |
Investing Cash Flow | -1.2B | -1.4B | -1.2B | -2.6B | -705.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -80.7M | -86.3M | -78.5M | - | - |
Debt Issuance | - | - | - | - | 555.3M |
Debt Repayment | - | -55.0M | -91.3M | -1.6B | - |
Financing Cash Flow | 377.4M | 1.0B | -169.8M | 2.1B | 562.6M |
Free Cash Flow | -393.0M | -1.7B | -650.6M | -38.0M | 357.2M |
Net Change in Cash | -795.3M | -843.8M | -844.7M | 503.5M | 2.7B |
Cash Flow Trend
Krsnaa Diagnostics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.30
Forward P/E
21.23
Price to Book
3.13
Price to Sales
3.87
PEG Ratio
21.23
Profitability Ratios
Profit Margin
10.82%
Operating Margin
16.68%
Return on Equity
9.17%
Return on Assets
5.19%
Financial Health
Current Ratio
1.36
Debt to Equity
23.06
Beta
-0.15
Per Share Data
EPS (TTM)
₹23.59
Book Value per Share
₹273.22
Revenue per Share
₹222.15
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
krsnaa | 27.8B | 36.30 | 3.13 | 9.17% | 10.82% | 23.06 |
Dr. Lal PathLabs | 268.6B | 52.27 | 12.35 | 22.08% | 20.29% | 7.14 |
Syngene | 262.6B | 51.97 | 5.56 | 10.50% | 13.61% | 12.23 |
Vimta Labs | 28.0B | 39.51 | 7.39 | 17.78% | 19.93% | 2.25 |
Suraksha Diagnostic | 15.5B | 49.96 | 7.35 | 15.14% | 12.44% | 42.28 |
Qualitek Labs | 3.0B | 42.74 | 3.10 | 12.27% | 8.97% | 37.74 |
Financial data is updated regularly. All figures are in the company's reporting currency.